You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

April 23, 2019

Vietnam Investment Review: CPTPP Obligations Alter Vietnam’s IP Landscape

Vietnam Investment Review (VIR)

Due to significant changes to the intellectual property (IP) landscape, the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) indeed poses major challenges to Vietnam in implementing its obligations. Most of the obligations aim to enhance protection for IP proprietors. This will have a particular impact on the life science sectors, benefitting foreign pharmaceutical and agrochemical companies but reducing opportunities, at least in the short-term, for Vietnamese companies.

The obligations under the CPTPP are widespread. The IP chapter of the agreement is the only chapter with obligations affecting both CPTPP members and other member countries of the World Trade Organization. Non-bloc countries with strong IP-based economies such as the EU and the US still enjoy protection at the same level as other CPTPP members.

Vietnam is turning to Industry 4.0 to drive the economy forward, and some Vietnamese companies are now developing IP-oriented products. Thus, as IP serves as an engine for the economy, Vietnam should make the most of the opportunity the CPTPP affords across various areas, including those set out below.

Enforcement

Under the CPTPP, Vietnam must boost the effectiveness of its fight against IP infringement. To this end, Vietnam must assume responsibility for making the enforcement system more transparent and equitable, guaranteeing public access to all its rulings. More significantly, Vietnam must additionally criminalise some IP offenses such as wilful import or export of counterfeit trademark goods or pirated copyright goods, wilful import and domestic use of counterfeit labels or packaging, recording, and trade secret infringement.

Pursuant to a resolution of the National Assembly, Vietnam will amend the prevailing Penal Code in the next three years to codify these crimes. Vietnam would also leave out the requirement for a complaint from the IP owner to take criminal action against counterfeiting.

Regarding border control, the CPTPP requires that a right holder be provided with specific information about a shipment at issue. The CPTPP also allows an ex officio seizure of counterfeits in transit, in a two-year transition, and exports in a three-year transition.

This regulation clears up the doubt whether export of goods could constitute IP infringement. The regulation will also nullify the current relevant provision of the Law on Customs, which spares goods in transit from sanctions.

The pact also requires Vietnam to either pinpoint statutory damages or provide for punitive damages. Currently, no punitive damages are available in Vietnam. As to statutory damages, Article 205.1(c) of the Law on Intellectual Property allows the plaintiff to claim damages, which are capped at VND500 million ($21,739). However, to this end, in addition to the rationale for the claim, the plaintiff must prove that it cannot establish the actual damages. Thus, in fact, this provision has never been effective in practice, and on balance of convenience, courts often refuse to apply the provision.

Trademarks

Under the CPTPP, within three years, Vietnam must set up a mechanism to register sound trademarks, and do its best to register scent trademarks. Currently, the country only protects visible trademarks.

The country must also revisit its approach in recognising the well-known status of a trademark. Currently, authorities acknowledge the well-known status of a mark only if the mark acquires a very high degree of public knowledge from almost every walk of life, a practice that conflicts with the commitments in the CPTPP.

Licence Recordal

The CPTPP eliminates the requirement for registering a trademark licence to establish the validity of such licence against a third party. The draft bill emphasises this elimination, and also sets out that the use of the trademark by the licencee would inure to the benefit of the trademark owner. However, the bill does not specify whether the use of the trademark by companies economically related to the trademark owner, such as affiliates and subsidiaries, also amounts to authorised use.

Licences for other registered IP such as patents still need to be registered to be enforceable against a third party. This presents hurdles to business transactions due to the vague definition of the term “third party”. Any entity other than the signatories, including banks and tax authorities, can claim to be the third party to such license agreement, which may complicate the performance of obligations under unregistered licences.

Domain Name Disputes

Currently, domain name dispute resolution is itself a matter of dispute between duelling authorities. The Ministry of Science and Technology, which administers IP matters, and the Ministry of Information and Communication (MIC), which administers internet matters, have thus far been unable to reach an agreement to set up effective regimes for resolving disputes involving country code top-level domains.

The CPTPP requires Vietnam to set up such a regime. In line with this provision, the National Assembly passed a resolution to require an amendment to Article 130.1(d) on cybersquatting of the Law on Intellectual Property. However, the draft bill does not set out the amendment. Rather, the Ministry of Industry and Trade, which took charge of drafting the bill, recommended the MIC revise the relevant provisions in Decree No.72/2013/ND-CP to reflect the CPTPP’s requirement.

It seems that the battle of domain name disputes between the two ministries still lingers.

Other IP Subject Matters

The CPTPP significantly expands the grace period for patent novelty, from six months to 12 months. Vietnam will need to extend the exceptions for determining novelty when assessing the patentability of an invention. The agreement also alludes to protection of geographical indications, especially in connection with trademarks, and affords protection to the translation or transliteration of geographical indications.

Commitments to Specific Industries

In the agrochemical industry, Vietnam must ensure data exclusivity for undisclosed clinical trial data or other data for agricultural products for 10 years.

Particularly, Vietnam’s regulatory agency must not grant marketing approval to unauthorised parties, for example generic manufacturers, based on data concerning the safety and efficacy of an approved product that has been submitted by other parties in either Vietnam or in other countries. Vietnam has a 10-year transition period to implement this obligation.

In the pharmaceutical sector, Vietnam must also establish a patent linkage system in connection with the marketing approval process.

Balance of Enforcement

The CPTPP seems to create more balanced treatment for entities accused of IP infringement. When the court does not find infringement, the court can award the defendant reasonable legal fees that it spends for the suit. Under the prevailing Law on Intellectual Property, only the plaintiff is entitled to such legal fee award.

In addition, the pact also allows Vietnam to punish the abuse of IP rights by the owner. The draft bill supplements Article 198 of the prevailing Law on Intellectual Property to lay down such regulation. However, the supplemented article does not go into detail about how to determine the abuse.

RELATED INSIGHTS​ 

May 2, 2025
Attorneys from Tilleke & Gibbins have updated the latest edition of Doing Business in Thailand, a Q&A-style guide from Thomson Reuters Practical Law that offers an overview of key legal considerations for companies operating in jurisdictions worldwide. The contribution outlines the country’s legal and regulatory framework for foreign investment and business operations and reflects the latest legislative developments. The chapter addresses the following core topics: Legal system: Structure of the courts and the codified nature of Thai law. Foreign investment: Business restrictions under the Foreign Business Act, sector-specific regulations, exchange control rules, and investment incentives. Business vehicles: Overview of partnerships, private and public limited companies, and other legal entities. Employment: Labor protections, employment contracts, foreign worker requirements, and termination procedures. Tax: Corporate and personal income tax, indirect taxes, and tax obligations for residents and non-residents. Intellectual property: Registration and enforcement of patents, trademarks, designs, and copyrights. Data protection: Key provisions of the Personal Data Protection Act and related compliance obligations. Competition law: Regulatory framework under the Trade Competition Act. Anti-bribery and corruption: Relevant legislation and enforcement mechanisms. E-commerce and digital business: Legal regime for online transactions and digital platforms. Marketing and advertising: Consumer protection laws and regulations affecting advertising and marketing practices. Product regulation and liability: Safety standards, liability regimes, and roles of enforcement authorities. Practical Law, a legal reference resource from Thomson Reuters, publishes a range of guides for hundreds of jurisdictions and practice areas. The insurance and reinsurance guide is a valuable resource for legal practitioners, covering numerous jurisdictions worldwide. To view the latest version of the guide, please visit the Practical Law website and enroll in the free Practical Law trial to gain full access.
March 7, 2025
On November 22, 2024, the Ministry of Health (MOH) in Laos issued Decision No. 3730/MOH, which regulates the management, processing, production, and use of biopharmaceutical products, genes, and stem cells. This decision came into force on January 18, 2025, 45 days after its publication in the Lao Official Gazette on December 4, 2024. This decision signifies Laos’ recognition and acceptance of biopharmaceutical products, genes, and stem cells for use in medical treatments and the beauty industry, and it aligns with the ongoing development of biomedical sciences in the country. Definitions The MOH’s decision defines biopharmaceuticals, gene therapy, and stem cells as follows: “Biopharmaceutical products” refers to a type of biological or drug product that is produced or synthesized from natural substances, objects, or chemicals. This group of products includes blood, blood components, allergens, cells or cellular components, gene therapies, tissues, protein-based medicines, drugs derived from living cells, and biologics, which can be produced from sugars, proteins, amino acids, or substances with complex characteristics derived from organic sources such as human, animal, and plant parts; yeast; and microorganisms. These products exclude vaccines and biosimilar products, which will be specified under separate regulations. “Gene therapy” refers to a treatment approach that applies the principle of arranging amino acids (which could involve DNA or RNA sent to the patient’s cells in the form of a drug with the purpose of treating a certain disease). “Stem cells” are defined in the decision as cells or immature cells that can be sourced from various organs in the They are characterized by being undifferentiated, having the potential for differentiation, and being self-renewing. Stem Cell Production The decision outlines comprehensive provisions for managing and using raw materials in stem cell production. Key points include: Production location standards: Ensuring facilities meet specific standards of the MOH. Personnel
December 13, 2024
Experts from Tilleke & Gibbins have provided updates for the latest edition of The Pharma Legal Handbook: Vietnam, published by Pharma Boardroom. This comprehensive guide to the legal framework regulating the healthcare and life sciences industries in Vietnam was authored by by the Hanoi-based team of Hien Thi Thu Vu, head of regulatory affairs for Vietnam, and Mai Thi Le, regulatory affairs consultant, the handbook is a must-read for healthcare and life sciences companies that are interested in the Vietnam market. The guide includes eight sections on various important aspects of local regulations: Regulatory, Pricing, and Reimbursement Overview Preclinical & Clinical Trial Requirements Marketing, Manufacturing, Packaging & Labeling, and Advertising Traditional Medicines and Over-the-Counter Products Product Liability Patents and Trademarks Regulatory Reforms Orphan Drugs and Rare Diseases Tilleke & Gibbins has also authored The Pharma Legal Handbook: Thailand, which was updated at the same time as the Vietnam guide. The Pharma Legal Handbook: Vietnam, like all of the country guides from Pharma Boardroom, is available for purchase on the Pharma Boardroom website.
December 13, 2024
Attorneys from Tilleke & Gibbins in Bangkok have provided updates for the latest edition of The Pharma Legal Handbook: Thailand, published by Pharma Boardroom. This comprehensive guide to the legal framework regulating the healthcare and life sciences industries in Thailand was authored by Alan Adcock, partner and director, intellectual property, and head of the firm’s life sciences practice; Dr. Atthachai Homhuan, manager of regulatory affairs; and San Chaithiraphant, senior associate. The handbook is a must-read for healthcare and life sciences companies that are interested in exploring expansion into the Thai market.